5-MBPB
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C13H17NO |
| Molar mass | 203.28 g/mol (freebase) 239.78 g/mol (hydrochloride) g·mol−1 |
| 3D model (JSmol) | |
| |
| |
5-MBPB (also known as 5-MPBP and 5-MABB) is an amphetamine derivative which is structurally related to MDMA and has been sold as a designer drug. It can be described as the benzofuran-5-yl analogue of MBDB or the butanamine homologue of 5-MAPB, and is also a structural isomer of 5-EAPB and 6-EAPB. Anecdotal reports suggest this compound has been sold as a designer drug in various European countries since early 2015, but the first definitive identification was made in December 2015 by a forensic laboratory in Slovenia.[1]
5-MBPB is similar in structure to compounds such as 5-APB which are claimed to be agonists of the 5-HT2C receptor.[2]
5-MBPB (5-MABB) has been found to act as a potent serotonin–norepinephrine–dopamine releasing agent, with preference for induction of serotonin release over norepinephrine and dopamine release, and fully substitutes for MDMA in animal drug discrimination tests.[3]
References
[edit]- ^ European Monitoring Center for Drugs and Drug Addiction – Europol 2015 Annual Report on the implementation of Council Decision 2005/387/JHA
- ^ US patent 7045545, Karin Briner et al, "Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists", published 2000-01-19, issued 2006-16-03
- ^ Johnson CB, Walther D, Baggott MJ, Baker LE, Baumann MH (September 2024). "Novel Benzofuran Derivatives Induce Monoamine Release and Substitute for the Discriminative Stimulus Effects of 3,4-Methylenedioxymethamphetamine". J Pharmacol Exp Ther. 391 (1): 22–29. doi:10.1124/jpet.123.001837. PMC 11413916. PMID 38272669.